PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Some net income increase while CRVO is negative at -209.86%. John Neff would see a short-term edge over the struggling competitor.
-0.50%
Negative yoy D&A while CRVO is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
15.92%
Deferred tax of 15.92% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
0.65%
Less SBC growth vs. CRVO's 172.12%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-31.26%
Both reduce yoy usage, with CRVO at -121.12%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
A yoy AP increase while CRVO is negative at -86.33%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-40.45%
Negative yoy usage while CRVO is 193.45%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-15.92%
Negative yoy while CRVO is 99.27%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
32.67%
Some CFO growth while CRVO is negative at -193.92%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above CRVO's 100.00%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Both yoy lines negative, with CRVO at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.